

CUA-GUMOC Community Medical Oncologists Regional Meeting



Calgary Edition

Friday, November 29, 2024 | 08:00-16:00

Sheraton Cavalier Calgary Hotel 2620 32nd Avenue NE Calgary, AB T1Y 6B8



Co-Chairs: Simon Mairs and Scott North

08:00 - 08:45	Arrivals and Breakfast
08:45 - 08:55	Welcome by co-chairs/introductions
	Simon Mairs & Scott North
08:55 - 09:00	CUA Clinical Tools Update Tiffany Pizioli
09:00 - 10:00	Playground Topics – We're in the Sandbox Together! Carissa Beaulieu
09:00 - 09:15	High Risk Localized Prostate Cancer – the role for adjuvant abiraterone
09:15 - 09:30	High risk resected Renal Cell Carcinoma – the role of adjuvant pembrolizumab
09:30 - 09:45	Muscle Invasive Urothelial Carcinoma – the role of adjuvant nivolumab
09:45 - 10:00	Q & A
10:00 - 10:40	Intensifying the mCSPC patient – Doublet versus Triplet and how do I choose? Michael Kolinsky
10:40 - 10:45	Q & A
10:45 - 11:00	Health Break with Exhibitors
11:00 - 11:25	The state of PSMA scans in Alberta and Radioisotope therapy- from Data to Access Steven Yip
11:25 - 11:30	Q & A
11:30 - 11:55	PARP inhibitors in prostate cancer management and Genetic Testing in Alberta Steven Yip
11:55 - 12:00	Q & A
12:00 - 13:00	Lunch
13:00 - 13:40	Current Landscape of Advanced Urothelial Carcinoma Management Nimira Alimohamed
13:40 - 13:45	Q & A
13:45 - 14:25	Current Management of Advanced Renal Cell Carcinoma Vishal Navani
14:25 - 14:30	Q & A
14:30 - 14:45	Health Break with Exhibitors
14:45 - 15:30	What the hell is this? Toxicity management of new agents and Connec Care Tips • Enfortumab Vedotin Nimira Alimohomed • Exceptional Care Plans in ConnectCare Jacolette Hattingh • Other ConnectCare tips/tricks/hacks Richard Littleton
15:30 - 16:00	Divide and Conquer: How can all practitioners work to scope to manage our patients?





16:00



Open forum discussion; possible topics

• Who does adjuvant abi in high-risk prostate







Closing remarks



Facilitated by Simon Mairs/Scott North/Abhijit Ghose

• Alternate schedule assessments in stable IO patients

GOLD SPONSORS

• Which provider can manage ARPI patients in metastatic disease







CONTRIBUTOR

